In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Renal Denervation Buzz: Separating Fact From Myth; Covidien Buys Maya Medical

Executive Summary

Renal denervation was clearly the belle of this year’s EuroPCR, with more than a dozen sessions on the topic. In addition, just preceding the meeting, Covidien announced its acquisition of RDN start-up Maya Medical.

Advertisement

Related Content

SYMPLICITY Results Make Life Difficult For Renal Denervation Programs
SYMPLICITY Results Make Life Difficult For Renal Denervation Programs
Device/Diagnostics Quarterly Deal Statistics, Q4 2012
Device Trends To Watch In 2013
The Medical Device Industry Stays The Course In 2012
Renal Denervation Land Grab Continues As Boston Scientific Buys Vessix
Medtech Investing: A Survivor’s Game
Device/Diagnostics Quarterly Deal Statistics, Q2 2012
Medical Device Market & Industry Briefs, September 2012
Renal Denervation: Device Market’s Gold Rush

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel